Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
NOS[1]
|
---|---|
ln Vitro |
In the absence of Aβ1-42, S-MTC dihydrochloride (10 or 100?μM) decreases cellular NO release. At 100?μM S-MTC dihydrochloride reduces the viability of cells. Comparing S-MTC dihydrochloride (100?μM) to the control (no exposure to NOS inhibitor; 19.6±1.2?μM), nitrite generation is dramatically reduced (11.2±1.1?μM). The amounts of nitrite produced following treatments with Aβ1-42 and L-NOARG (100?μM) or Aβ1-42 and S-MTC dihydrochloride (100?μM) are substantially less than when Aβ1-42 is used alone (33.5±2.0 and 34.5±1.6μM, respectively). When delivered following Aβ1-42 at the 1?h time point. The concentration of S-MTC dihydrochloride (100?μM) reduces the levels of MTT (87±1% of control) and NR (80±1% of control, respectively). The effects of Aβ1-42 alone are dramatically reversed when S-MTC dihydrochloride (100?μM) and Aβ1-42 are administered together (72±2% vs. 61±2% of control)[1].
|
ln Vivo |
S-methyl-L-thiocitrulline, or S-MTC dihydrochloride, is a neuronal NOS inhibitor that is selective. Pretreatment with S-MTC dihydrochloride (icv) considerably attenuates the HBO2-induced antinociception. Pretreatment with naltrexone hydrochloride (NTX) (3.0 mg/kg, ip), L-NAME (1.0 μg/mouse, icv), S-MTC dihydrochloride (1.0 μg/mouse, icv), or N5-(1-iminoethyl)- L-ornithine (L-NIO) (3.0 mg/kg, sc) is administered to distinct mouse groups in Experiment #2 15–30 minutes before HBO2 treatment. When the antinociceptive effect is measured 90 minutes after HBO2 treatment, NTX and L-NAME totally eliminate it, S-MTC dihydrochloride antagonizes two third of it, and L-NIO mainly has no impact (F=25.57, p<0.0001)[2]. S-MTC dihydrochloride (SMTC) raises mean blood pressure (BP) at a dose of 0.3 mg/kg. S-MTC dihydrochloride produces heart rate reductions, blood pressure increases, and vasoconstriction in all three vascular beds at dosages of 1.0, 3.0, and 10 mg/kg[3].
|
References |
[1]. Law A, et al. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br J Pharmacol. 2001 Aug;133(7):1114-24.
[2]. Zelinski LM, et al. A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygenin mice. J Pain. 2009 Feb;10(2):167-72. [3]. Wakefield ID, et al. Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br J Pharmacol. 2003 Jul;139(6):1235-43. |
Molecular Formula |
C7H17CL2N3O2S
|
---|---|
Molecular Weight |
278.20
|
CAS # |
209589-59-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CSC(=N)NCCC[C@@H](C(=O)O)N.Cl.Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5945 mL | 17.9727 mL | 35.9454 mL | |
5 mM | 0.7189 mL | 3.5945 mL | 7.1891 mL | |
10 mM | 0.3595 mL | 1.7973 mL | 3.5945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.